CORT — Corcept Therapeutics Incorporated stock price, charts and financials

NASDAQ·Healthcare·Medical - Pharmaceuticals·USA

Latest market price

113.77

+2.99+2.70%

Overview Short InterestFilings

CORTQT76Corcept Therapeutics Incorporated·NASDAQ

Overview Short InterestFilings

113.77+2.70%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

LQDA+0.91%$91.04 KNSA+1.04%$76.85 RPRX+1.15%$57.42 TRLV+1.60%$8.89 DVA-0.64%$182.60 MDGL+0.84%$514.30 HALO-0.22%$102.89 BTSG-1.18%$61.69

Snapshot

Index	-	P/E	-	EPS (ttm)	0.52	Insider Own	9.19%	Shs Outstand	108.10M	Perf Week	-3.25%

Market Cap	11.97B	Forward P/E	29.51	EPS next Y	3.75	Insider Trans	-4.77%	Shs Float	90.57M	Perf Month	18.79%

Enterprise Value	11.87B	PEG	-	EPS next Q	0.65	Inst Own	-	Short Float	10.43%	Perf Quarter	116.98%

Income	56.28M	P/S	14.41	EPS this Y	382.14%	Inst Trans	-	Short Ratio	8.58	Perf Half Y	188.76%

Sales	830.81M	P/B	16.54	EPS next Y	85.37%	ROA	6.18%	Short Interest	9.44M	Perf YTD	218.30%

Book/sh	-	P/C	106.40	EPS next 5Y	61.01%	ROE	8.37%	52W High	125.51 -9.36%	Perf Year	57.08%

Cash/sh	-	P/FCF	111.99	EPS past 3/5Y	-1.95% -0.72%	ROIC	0.87%	52W Low	29.43 286.50%	Perf 3Y	342.90%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.70% 16.54%	Gross Margin	98.30%	Volatility	3.50% 5.21%	Perf 5Y	433.32%

Dividend TTM	-	EV/Sales	14.29	EPS Y/Y TTM	-65.85%	Oper. Margin	0.77%	ATR (14)	5.37	Perf 10Y	1790.27%

Dividend Ex-Date	-	Quick Ratio	2.77	Sales Y/Y TTM	23.11%	Profit Margin	6.61%	RSI (14)	64.27	Recom	2.58

Dividend Gr. 3/5Y	-	Current Ratio	2.86	EPS Q/Q	24.14%	SMA20	11.92%	Beta	0.44	Target Price	117.60

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	31.96%	SMA50	24.94%	Rel Volume	0.63	Prev Close	110.77

Employees	730	LT Debt/Eq	0.01	Earnings	Nov 03	SMA200	76.85%	Avg Volume	1.17M	Price	113.77

IPO Date	Apr 14, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	1383.25% 15.83%	Net Debt/EBITDA	-3.53	Volume	737,334	Change	2.70%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	HC Wainwright & Co.	Buy	$95 → $165
Jul-29-26	Reiterated	Canaccord Genuity	Buy	$100 → $150
Jul-27-26	Downgrade	Wolfe Research	Peer Perform → Underperform	$30 → $50
May-28-26	Reiterated	UBS	Buy	$110 → $135
May-28-26	Reiterated	HC Wainwright & Co.	Buy	$75 → $95
May-13-26	Upgrade	UBS	Neutral → Buy	$95 → $72
May-04-26	Reiterated	HC Wainwright & Co.	Buy	$67 → $75
May-01-26	Reiterated	Piper Sandler	Overweight	$38 → $88
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Feb-20-26	Reiterated	HC Wainwright & Co.	Buy	$105 → $67

Latest News

Aug-05-26

Aug-05-2610:51AM

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Termzacks.com

06:47AM

Raised Guidance Lifts Corcept to 52-Week Highfxempire.com

Aug-03-26

Aug-03-2605:23AM

FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORTdefenseworld.net

Aug-01-26

Aug-01-2603:49AM

Avidity Partners Management LP Has $1.21 Million Position in Corcept Therapeutics Incorporated $CORTdefenseworld.net

Jul-31-26

Jul-31-2611:34AM

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows Itseekingalpha.com

Jul-30-26

Jul-30-2601:06PM

CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raisedzacks.com

Jul-29-26

Jul-29-2607:33PM

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcriptseekingalpha.com

07:26PM

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimateszacks.com

06:04PM

Corcept Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

04:05PM

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Updatebusinesswire.com

Jul-27-26

Jul-27-2608:01AM

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For MondayBenzinga

Jul-23-26

Jul-23-2610:41AM

Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?zacks.com

Jul-22-26

Jul-22-2604:05PM

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Callbusinesswire.com

06:31AM

These major drug stocks rally after Trump's zero tariff announcementfinbold.com

Jul-21-26

Jul-21-2607:57AM

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?fool.com

Company

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	831	761	675	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	15	13	11	—	—	—	—	—	—
Gross Profit	817	748	664	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	556	449	280	—	—	—	—	—	—
Research and Development	254	255	247	—	—	—	—	—	—
Other Operating Expense	1	0	0	—	—	—	—	—	—
Operating Income	5	45	137	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	20	22	25	—	—	—	—	—	—
Net Income Before Taxes	26	66	161	—	—	—	—	—	—
Income Taxes	-35	-33	20	—	—	—	—	—	—
Consolidated Net Income	55	100	140	—	—	—	—	—	—
Net Income From Continuing Operations	62	100	141	—	—	—	—	—	—
Net Income	55	100	140	—	—	—	—	—	—
EPS (Recurring)	0.52	0.95	1.35	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.52	0.95	1.35	—	—	—	—	—	—
EPS (Diluted)	0.42	0.82	1.23	—	—	—	—	—	—
EBITDA	29	68	163	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	270.87	42.44	40.97	—	—	—	—	—	—
Price To Sales Ratio	14.37	4.76	7.69	—	—	—	—	—	—
Gross Margin	98.32	98.29	98.37	—	—	—	—	—	—
Operating Margin	0.60	5.91	20.30	—	—	—	—	—	—
Net Margin	6.62	13.14	20.74	—	—	—	—	—	—
Shares Outstanding	105	104	103	—	—	—	—	—	—
Market Capitalization	11,945	3,619	5,190	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Chief Development Officer	Aug 04 '26	Option Exercise	21.65	3,700	80,105	7,685	Aug 06
Guyer William	Chief Development Officer	Aug 04 '26	Sale	113.12	3,700	418,562	3,985	Aug 06
Maduck Sean	See Remarks	Aug 03 '26	Sale	114.70	20,305	2,329,075	9,755	Aug 05
Maduck Sean	See Remarks	Aug 03 '26	Option Exercise	8.27	20,305	167,922	30,060	Aug 05
Lyon Joseph Douglas	See Remarks	Aug 03 '26	Sale	114.16	1,540	175,806	5,495	Aug 05
Mokari Atabak	Chief Financial Officer	Jul 30 '26	Sale	114.71	80,000	9,177,109	16,130	Aug 03
Mokari Atabak	Chief Financial Officer	Jul 30 '26	Option Exercise	23.06	80,000	1,844,800	96,130	Aug 03
WILSON JAMES N	Director	Jul 15 '26	Sale	88.30	10,000	882,985	1,084,543	Jul 17
Mokari Atabak	Chief Financial Officer	Jul 15 '26	Option Exercise	21.56	40,000	862,235	56,130	Jul 17
Mokari Atabak	Chief Financial Officer	Jul 15 '26	Sale	87.71	40,000	3,508,277	16,130	Jul 17
Guyer William	Chief Development Officer	Jul 07 '26	Option Exercise	21.65	20,000	433,000	23,985	Jul 08
Guyer William	Chief Development Officer	Jul 07 '26	Sale	93.13	20,000	1,862,529	3,985	Jul 08
Maduck Sean	See Remarks	Jul 01 '26	Sale	88.35	25,000	2,208,737	9,755	Jul 06
Maduck Sean	See Remarks	Jul 01 '26	Option Exercise	8.27	25,000	206,750	34,755	Jul 06
MAHONEY DAVID L	Director	Jun 17 '26	Sale	84.53	20,000	1,690,506	26,147	Jun 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.